Ivan D. Horak

Biography

 Dr. Ivan D. Horak, M.D, FACP has been Head of Global R&D, Chief Scientific & Medical Officer of Symphogen A/S since August 07, 2017. Dr. Horak served as Chief Scientific & Medical Officer of Symphogen A/S since April 16, 2011. Dr. Horak has been Chief Scientific Officer and Executive Vice President of Research and Development of Evivrus Inc., since September 2005. He has an impressive background in drug development. He served as the Chief Scientific Officer of Enzon Pharmaceuticals Inc. from September 2005 to April 4, 2011, President of Research & Development from February 22, 2010 to April 4, 2011 and as its Executive Vice President of Research & Development from September 2005 to February 22, 2010. He oversaw all aspects of Enzon's research and development, regulatory affairs and quality assurance activities. He served as Chief Scientific Officer of Immunomedics Inc., from July 2003 to September 2005 and as Executive Vice President for Research and Development from May 2002 to July 2003. Prior to that, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he directed global development of oncology compounds from 1999 to 2002, including Camptosar(R) for metastatic colorectal cancer. From 1996 to 1999, he held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of Johnson & Johnson, including Director, Research & Development. From 1986 to 1995, Dr. Horak served as with the National Cancer Institute, where he studied the role of non-receptor tyrosine kinases in hematologic malignancies. He has held senior research leadership positions in R & D at Pharmacia & Upjohn. He has held a number of senior medical and scientific positions in the pharmaceutical industry, as well as the National Cancer Institute (NCI).

Research Interest

 His work has resulted in over 40 publications related to cancer. He serves on the editorial board of Cancer Research. He has been Co-Chairman Scientific Advisory Board at Symphogen A/S since August 18, 2015. Dr. Horak is active in a number of scientific and medical societies, including the American Association for Cancer Research, American Society of Hematology, the International Union against Cancer and American Society of Clinical Oncology. He is board certified in both Internal Medicine and Medical Oncology, with multiple NDAs to his credit, Camptosar in Metastatic colorectal cancer, Aromasin for patients with advanced breast cancer and Oncaspar for patients with acute lymphoblastic leukemia. He is a Fellow of the American College of Physicians. Dr. Horak received his M.D. degree from the University of Komenius, Bratislava, Czechoslovakia.